Analyst Price Target is C$8.00
▼ -27.73% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is C$8.00, with a high forecast of C$8.00 and a low forecast of C$8.00. The average price target represents a -27.73% upside from the last price of C$11.07.
Current Consensus is
The current consensus among 1 investment analysts is to hold stock in Bausch Health Companies. This Hold consensus rating has held steady for over two years.
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.